about
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cellsYin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implicationStem cells and targeted approaches to melanoma cureProgression of cutaneous melanoma: implications for treatmentCEACAM1: Expression and Role in Melanocyte TransformationHost risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men.High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinomaEmerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancerSOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancerEvaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines.SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.CEACAM1 promotes melanoma cell growth through Sox-2.Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.Association between tumorigenic potential and the fate of cancer cells in a syngeneic melanoma model.Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity.5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsiesNestin depletion induces melanoma matrix metalloproteinases and invasionA CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.Roles of sex-determining region Y-box 2 in cell pluripotency and tumor-related signaling pathways.Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An UpdatemicroRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma.Oxidized low density lipoprotein, stem cells, and atherosclerosis.SOX2 and cancer: current research and its implications in the clinicMicrophthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation.MiR-429 suppresses glioblastoma multiforme by targeting SOX2.The overexpression of SOX2 affects the migration of human teratocarcinoma cell line NT2/D1.Melanoma spheroid formation involves laminin-associated vasculogenic mimicry.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.SOX2 modulates levels of MITF in normal human melanocytes, and melanoma lines in vitroDominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients.Neural stem/progenitor cells react to non-glial cns neoplasms.Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation.SOX2 expression in the developing, adult, as well as, diseased prostateExpression of OCT-4 and SOX-2 in Bone Marrow-Derived Human Mesenchymal Stem Cells during Osteogenic DifferentiationA multigene support vector machine predictor for metastasis of cutaneous melanoma.Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.Sox2 is dispensable for primary melanoma and metastasis formation.Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma.
P2860
Q21559479-A08556F9-2FDC-4649-BD84-3D280AD7DABAQ26745972-9D2DC6C0-270A-4AF1-A753-5881B2E76D10Q26825014-6386AFE7-E67A-4B2B-AF90-153B5B081442Q27001734-9E49D308-D05E-48BA-9FE5-484D22DB8977Q28072724-CD5B0C78-0134-4826-BFB5-1A4B7A23666CQ33621151-5D4131AF-C326-4A65-9787-2790CA19E6E8Q33755780-D4A74B9C-1333-4462-9A78-CE3004CC9697Q33875325-6627C66B-900C-4491-B1A4-7CDBDDBB2AE2Q33882664-96250DB8-A787-495D-B4CE-7767FB9006BEQ33935045-3CF5128A-168A-487F-8F67-9B0E9AB3EE73Q34174419-8EB456F0-7B52-4630-ADE3-D0DE5AC03293Q34269756-60A5836C-9FB2-45FA-A166-EB1BD7DA9B50Q34346442-DB527EC7-93D2-4FDB-B0F9-216E523DA968Q34410160-70FCA710-06D0-45E8-BB0B-FD1910A5D7AAQ34692759-0BD9E9D3-CFE3-4EFD-B160-49160E82A731Q34788271-FDD8F248-E100-4FE4-8EF8-EF33658428B3Q35033583-461ABAB8-A9C0-456B-AFE6-55D911C6BCD0Q35569170-E7A393B3-DE06-47F8-AA72-5394C35E35C3Q35782988-D93B6AE2-90DF-486D-9C8B-1D97151CAB29Q36334636-4137969A-D21D-49DA-8974-9DE0B43EE340Q36752423-770E2520-9D0A-4CF6-B6EB-5B95E08E5CEFQ37706588-E10BAF95-ADBC-4546-8299-A4816BE4A813Q38022767-C9E1CDD9-21F0-4D09-8407-7CA0F3747A8EQ38239137-70567179-127E-492C-B7BD-DCECA44C75A6Q38417606-0E610561-5DEF-4A46-9F48-F1E973CCA9B8Q38696293-158A9EC1-7EA6-4B27-A6FD-F9A10A0B4FF6Q38901084-07344506-A9F3-438D-B1BA-CC6EC1398B35Q39044293-1A9193AD-E2B2-4D80-9D1A-A6FEFD985355Q39107981-F8878E2A-3129-434F-8FFA-595280B95803Q39351432-008057F4-4568-4281-82F9-A1C8BB7A7092Q41763430-714A0EDA-B6CF-4F76-8856-AC8A5ACFEC70Q41873088-027810FA-D713-461A-8E4C-9608C4059381Q41991455-56D52B19-F30C-4DF5-9123-20E5B3F60E23Q42463444-C297BF40-970D-431B-8A5A-FF8AFB58E364Q42572074-CF82817D-9F53-41CA-85D3-4234B1F98F55Q47173520-241CDD45-302E-4700-9977-D3C4D1CC1F9DQ49450264-03574DBB-5929-4062-ABF2-ED4FC9DFF1EFQ51075741-6CF877C2-D802-4F6A-A9BF-DEF5D56F678BQ51075761-16DCF317-FD8F-40EC-9D61-27FF69F8216CQ51832556-DB7B90B0-10D5-488D-B876-EA23E91FFFA9
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
SOX2 contributes to melanoma cell invasion.
@en
SOX2 contributes to melanoma cell invasion.
@nl
type
label
SOX2 contributes to melanoma cell invasion.
@en
SOX2 contributes to melanoma cell invasion.
@nl
prefLabel
SOX2 contributes to melanoma cell invasion.
@en
SOX2 contributes to melanoma cell invasion.
@nl
P2093
P2860
P1476
SOX2 contributes to melanoma cell invasion.
@en
P2093
Alvaro C Laga
Chung-Wei Lee
George F Murphy
Hans R Widlund
John F Thompson
Martin C Mihm
Sasha D Girouard
P2860
P2888
P304
P356
10.1038/LABINVEST.2011.188
P577
2011-12-19T00:00:00Z